share_log

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K:外国发行人报告
美股SEC公告 ·  09/16 06:21

Moomoo AI 已提取核心信息

NeuroSense Therapeutics Ltd., a foreign private issuer, has filed a report with the United States Securities and Exchange Commission (SEC) for the month of September 2024. The report, submitted on Form 6-K, indicates that NeuroSense Therapeutics has begun the process of complying with the Health Insurance Portability and Accountability Act (HIPAA) regulations. This initiative is part of the company's regulatory obligations in the United States. The filing, dated September 16, 2024, was signed by Alon Ben-Noon, an authorized representative of NeuroSense Therapeutics.
NeuroSense Therapeutics Ltd., a foreign private issuer, has filed a report with the United States Securities and Exchange Commission (SEC) for the month of September 2024. The report, submitted on Form 6-K, indicates that NeuroSense Therapeutics has begun the process of complying with the Health Insurance Portability and Accountability Act (HIPAA) regulations. This initiative is part of the company's regulatory obligations in the United States. The filing, dated September 16, 2024, was signed by Alon Ben-Noon, an authorized representative of NeuroSense Therapeutics.
NeuroSense Therapeutics Ltd.,一家外国私人发行人,已向美国证券交易委员会(SEC)提交了2024年9月的报告。该报告是以6-k表格提交的,表明NeuroSense Therapeutics已经开始遵守《健康保险移植与责任法案》(HIPAA)的法规。这一举措是公司在美国的监管义务的一部分。文件日期为2024年9月16日,由NeuroSense Therapeutics的授权代表Alon Ben-Noon签署。
NeuroSense Therapeutics Ltd.,一家外国私人发行人,已向美国证券交易委员会(SEC)提交了2024年9月的报告。该报告是以6-k表格提交的,表明NeuroSense Therapeutics已经开始遵守《健康保险移植与责任法案》(HIPAA)的法规。这一举措是公司在美国的监管义务的一部分。文件日期为2024年9月16日,由NeuroSense Therapeutics的授权代表Alon Ben-Noon签署。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息